Vaginal Estrogen and Prasterone: What Pelvic Health Rehabilitation Professionals Need to Know
Understanding genitourinary syndrome of menopause, local hormone therapy, and why tissue health matters in rehabilitation
The Tissue Behind the Symptoms
Pelvic health rehabilitation professionals see it every week. The patient whose painful intercourse plateaus despite excellent pelvic floor downtraining. The patient whose urinary urgency persists despite improved pelvic floor coordination. The patient who cannot tolerate a dilator, pessary, or internal examination.
Sometimes, the limiting factor isn't the muscle, it's the tissue.
Genitourinary syndrome of menopause (GSM) describes a collection of vulvovaginal, urinary, and sexual symptoms associated with declining estrogen and androgen concentrations during the menopausal transition.
GSM is common, frequently underrecognized, and often undertreated. Unlike vasomotor symptoms, which may improve over time, GSM symptoms frequently persist or worsen without appropriate management.
For pelvic health rehabilitation professionals, this matters.
We may not prescribe hormonal medications, but we are often the clinicians examining the tissues, identifying barriers to rehabilitation, and hearing the questions patients haven't felt comfortable asking their medical providers. Understanding the role of low-dose vaginal estrogen and vaginal prasterone (DHEA) allows us to educate accurately, refer appropriately, and advocate for more comprehensive care.
Because sometimes improving pelvic floor function requires addressing the health of the tissues surrounding it.
What Does Local Hormone Therapy Actually Do?
Two local hormonal treatments commonly discussed in GSM management are low-dose vaginal estrogen and vaginal prasterone. Although both may improve vulvovaginal symptoms, they work through different mechanisms.
Low-dose vaginal estrogen is available in several formulations, including creams, tablets, inserts, and low-dose vaginal rings. It acts on estrogen-responsive tissues in the vagina and lower urinary tract.
Vaginal prasterone, also known as dehydroepiandrosterone (DHEA), is administered as a vaginal insert. DHEA serves as a precursor that local tissues can convert into estrogens and androgens.
Current guidelines recognize both as treatment options for GSM, although low-dose vaginal estrogen has the most extensive evidence base.
Vaginal Tissue Health
Declining estrogen contributes to changes in vaginal epithelial thickness, lubrication, elasticity, and tissue integrity. Local hormone therapy can improve several of these tissue characteristics, potentially reducing dryness, irritation, and discomfort with penetration.
For our patients, these changes may translate into improved tolerance of activities such as intercourse, dilator use, pessary management, or pelvic floor examination. And that can change what becomes possible in rehabilitation.
Urinary Health
The urinary benefits of vaginal estrogen deserve particular attention. The urethra and lower urinary tract are influenced by the hormonal changes associated with menopause.
Evidence supports low-dose vaginal estrogen for reducing recurrent urinary tract infections in appropriately selected peri- and postmenopausal patients. It may also improve some urinary symptoms, including urgency and frequency, particularly when GSM coexists with other lower urinary tract conditions.
However, the evidence is not equally strong for every urinary outcome, and vaginal estrogen should not be presented as a universal treatment for urinary incontinence. Prasterone has substantially less research supporting urinary benefits.
Clinical takeaway: A patient with recurrent UTIs, vaginal dryness, and urinary urgency may have overlapping contributors to her symptoms. Pelvic floor rehabilitation remains valuable, but tissue health may warrant additional medical management.
Sexual Health
Both vaginal estrogen and prasterone have demonstrated benefits for GSM-related dyspareunia. Prasterone has been studied specifically for moderate to severe pain with sexual activity associated with vulvovaginal atrophy, with some studies reporting improvements in additional sexual function outcomes.
However, improvements in sexual function should not be interpreted as evidence that either treatment independently resolves all contributors to sexual dysfunction.
Pain with intercourse is rarely a single-system problem. Pelvic floor muscle function, tissue health, neural sensitivity, psychosocial factors, relationship dynamics, and sexual health concerns may all contribute. Treating the tissue may remove one barrier. Rehabilitation and mental health practice helps address the others.
What About the Risks?
For many patients, the word estrogen immediately raises concerns about breast cancer, cardiovascular disease, or blood clots. Much of this concern comes from research involving systemic menopausal hormone therapy.
But low-dose vaginal estrogen and systemic hormone therapy are not interchangeable when discussing exposure, benefits, or risk.
Cardiovascular Disease, Blood Clots, and Cancer
Large observational studies, including data from the Women's Health Initiative, have not identified an increased risk of major cardiovascular events or several cancers among users of vaginal estrogen compared with nonusers. These findings are reassuring.
However, observational evidence does not establish that every formulation is risk-free for every patient. The distinction between local and systemic therapy—and the patient's individual medical history—remains important.
What About Patients With a History of Breast Cancer?
This is an area where thoughtful, interdisciplinary decision-making is essential. Observational research and systematic reviews have generally been reassuring regarding vaginal estrogen use among breast cancer survivors.
However, a Danish observational study identified a possible increased recurrence risk in the subgroup using vaginal estrogen while receiving aromatase inhibitors. These findings warrant particular caution and individualized discussion.
For patients with a history of hormone-sensitive cancer, decisions about local hormone therapy should involve the prescribing clinician and oncology team, with consideration of nonhormonal options, symptom severity, treatment goals, and patient preferences.
Our role is not to independently determine whether hormonal treatment is appropriate. Our role is to recognize the problem and facilitate an informed conversation.
Endometrial Safety
Available studies suggest that endometrial complications are uncommon with appropriately prescribed low-dose vaginal estrogen, although long-term evidence remains more limited than short-term data. Routine addition of a progestogen is generally not required with low-dose vaginal estrogen, but unexpected bleeding requires medical evaluation.
Any postmenopausal bleeding warrants assessment—not reassurance based on presumed treatment effects.
What Changed With the FDA Boxed Warning?
In November 2025, the FDA initiated changes to menopausal hormone therapy labeling, including removal of certain boxed-warning risk statements. In February 2026, the FDA approved revised labeling for an initial group of products, including a topical vaginal estrogen product.
These changes reflect efforts to distinguish risks associated with different hormone therapy formulations and improve risk communication. Importantly, the labeling changes do not mean that all hormone therapies are risk-free or that every warning has been eliminated.
For pelvic health clinicians, the message is straightforward: Help patients distinguish the risks of systemic hormone therapy from the evidence surrounding low-dose local vaginal treatment.
When Can Women Start—and Is It Ever Too Late?
GSM is not restricted to women who are several years beyond menopause. Symptoms may begin during perimenopause, when hormone levels fluctuate and patients may still be menstruating.
Dryness, burning, pain with penetration, and new urinary symptoms deserve appropriate evaluation regardless of whether a patient has reached her final menstrual period. Most treatment trials have focused on postmenopausal populations, so treatment decisions during perimenopause should be individualized by the prescribing clinician.
At the other end of the spectrum, there is no universal age cutoff for initiating low-dose vaginal estrogen. The commonly discussed timing considerations for starting systemic menopausal hormone therapy—particularly age and years since menopause—should not automatically be applied to low-dose vaginal treatment.
A woman in her seventies experiencing recurrent UTIs or bothersome GSM symptoms may still be an appropriate candidate following medical evaluation.
How Long Does It Take to Work?
Some patients begin noticing improvement within several weeks, although meaningful symptom improvement may take longer. Response depends on the formulation, symptom severity, tissue condition, and individual factors.
Because GSM is associated with ongoing hormonal changes, symptoms may return when effective treatment is discontinued. Long-term management is therefore common, with periodic reassessment of symptoms, preferences, and treatment response.
Local Versus Systemic: How Much Hormone Reaches the Bloodstream?
One of the most common questions patients ask is: “If I use vaginal estrogen, how much gets into the rest of my body?”
Rather than estimating what percentage stays in the vaginal tissue, research evaluates systemic absorption by measuring circulating hormone concentrations. With many low-dose vaginal estradiol formulations, systemic absorption is minimal, and serum estradiol concentrations generally remain within the postmenopausal range.
However, absorption varies with the formulation, dose, timing, and condition of the vaginal epithelium. Minimal systemic absorption does not mean zero systemic absorption. That distinction is particularly relevant when counseling patients receiving aromatase inhibitors.
Prasterone works differently. Vaginal tissues convert DHEA into active estrogenic and androgenic metabolites locally, and clinical studies have generally demonstrated circulating hormone concentrations within postmenopausal ranges. Still, its safety and effectiveness should be considered separately from vaginal estrogen rather than assuming the two treatments are interchangeable.
What About Vaginal Moisturizers?
Not every patient wants, needs, or can use hormonal treatment. And this is where non-hormonal vaginal moisturizers become an important part of the conversation.
One popular product example is Revaree, an over-the-counter vaginal moisturizer containing hyaluronic acid, a substance that helps retain moisture. Unlike estrogen or prasterone, hyaluronic acid does not act through sex hormone receptors.
Can Moisturizers Be Effective?
Yes. Nonhormonal moisturizers can improve vaginal dryness and discomfort, particularly for patients with mild symptoms or those who prefer to avoid hormonal therapy.
A randomized pilot trial comparing vaginal hyaluronic acid with vaginal estrogen demonstrated symptom improvement in both groups over 12 weeks. However, a small pilot study cannot establish that the treatments are equivalent for all patients or outcomes.
Low-dose vaginal estrogen has a more substantial evidence base for GSM and recurrent UTI prevention.
Can Moisturizers and Vaginal Hormone Therapy Be Used Together?
Yes. They may be used as complementary approaches. Moisturizers provide non-hormonal symptom relief, while local hormonal treatments address hormone-responsive tissue changes.
The specific products, application schedule, tolerability, and compatibility should be reviewed with the prescribing clinician or pharmacist. Moisturizers and local hormone therapy are not necessarily competing interventions. The right combination depends on the patient's symptoms, preferences, medical history, and response.
Can Vaginal Estrogen Be Used Alongside Systemic Hormone Therapy?
Yes—and this is another important distinction for pelvic health clinicians.
A patient may be using systemic menopausal hormone therapy and still experience vaginal dryness, painful intercourse, urinary symptoms, or recurrent UTIs. Systemic therapy does not consistently resolve every GSM symptom.
For patients with persistent symptoms, clinicians may consider adding low-dose vaginal estrogen or vaginal DHEA as part of an individualized treatment plan. When GSM is the primary concern and systemic treatment is not otherwise indicated, local treatment may be an appropriate option without initiating systemic hormone therapy.
The important point is that being on systemic hormones does not automatically mean the genitourinary tissues are adequately treated. For rehabilitation professionals, persistent symptoms should prompt continued assessment and referrals to appropriate providers—not an assumption that hormonal factors have already been addressed.
Q&A: Answering the Questions Patients Ask Us
These responses can help clinicians communicate accurately while keeping prescribing decisions within the appropriate medical scope.
“I was told estrogen causes breast cancer. Is the vaginal kind safe?”
Low-dose vaginal estrogen is different from systemic estrogen therapy. Research has generally been reassuring regarding its safety, with minimal systemic absorption for many formulations. Your medical history still matters, so your prescribing clinician can help determine whether it is appropriate for you.
“I've had breast cancer. Is vaginal estrogen completely off the table?”
Not necessarily. There are situations where local treatment may be considered, but the decision should involve your oncology team, especially if you're taking an aromatase inhibitor. Non-hormonal options are also available.
“I'm still having periods. Am I too young?”
Not necessarily. Some vaginal and urinary changes begin during perimenopause. Your symptoms and medical evaluation matter more than reaching a particular age.
“I'm 75. Isn't it too late?”
No. The timing considerations often discussed for starting systemic hormone therapy do not apply in the same way to low-dose vaginal estrogen. Treatment can still be considered later in life.
“How long until I notice a difference?”
Some women notice improvement within a few weeks, while others need longer. Your prescriber can help you understand what to expect and when to reassess your response.
“Does vaginal estrogen get into my bloodstream?”
A small amount can be absorbed, but systemic exposure is generally very low with appropriately prescribed low-dose products. The amount depends on the formulation and dose.
“I keep getting UTIs. Could vaginal estrogen help?”
Possibly. Vaginal estrogen has evidence supporting its use to reduce recurrent UTIs in peri- and postmenopausal women. It's worth discussing with the clinician managing your urinary symptoms.
“I'm already on an estrogen patch. Why would I need vaginal estrogen too?”
Systemic estrogen doesn't always fully address vaginal or urinary symptoms. Some patients benefit from adding local treatment.
“Can I use Revaree or another moisturizer instead?”
For some patients, a non-hormonal moisturizer provides sufficient relief. Others benefit from prescription treatment, particularly when symptoms are persistent or involve recurrent UTIs. Your preferences and medical history should guide the discussion.
“What's the difference between estrogen and prasterone?”
Vaginal estrogen delivers estrogen directly to local tissues. Prasterone is DHEA, which vaginal tissues convert into estrogenic and androgenic metabolites. Both may improve vaginal dryness and pain with intercourse, but their evidence bases and approved uses differ.
What This Means for Pelvic Health Rehabilitation
Here is where this conversation becomes especially important for our profession.
We can provide excellent pelvic floor downtraining. We can improve muscle coordination. We can address neural sensitivity, movement strategies, breathing mechanics, and graded exposure. We can help patients regain confidence with penetration, movement, and sexual activity.
But if the tissues themselves remain irritated, dry, fragile, or poorly tolerant of mechanical loading, rehabilitation may continue to encounter barriers. That doesn't mean every patient with persistent symptoms needs vaginal estrogen.
It means we need to recognize when tissue health may be contributing to the presentation.
Screen Beyond the Muscles
Ask about vaginal dryness, burning, irritation, painful penetration, urinary urgency, frequency, and recurrent UTIs. These symptoms may not be volunteered unless we ask directly.
Assess and Document Tissue Findings
When appropriate and within scope, examine for tissue changes such as pallor, dryness, reduced rugae, fissuring, introital sensitivity, and discomfort with contact.
These findings are not independently diagnostic of GSM, but they may strengthen the clinical picture and help guide referral.
Refer With Clinical Specificity
Rather than simply advising a patient to “ask about estrogen,” communicate what you've identified.
For example:
The patient demonstrates persistent introital discomfort, vaginal dryness, and limited tolerance of graded penetration despite improvements in pelvic floor muscle relaxation and coordination. Medical assessment for possible GSM and discussion of appropriate local treatment options may be beneficial.
That gives the referring clinician meaningful information.
Educate Without Prescribing
Patients benefit from understanding that local hormone therapy, nonhormonal moisturizers, and pelvic health rehabilitation address different contributors to symptoms.
We can explain the general evidence, discuss available options, and encourage informed conversations with the prescribing team.
Follow Up on Barriers to Treatment
Cost, application preferences, irritation, uncertainty about safety, and difficulty maintaining a routine can all affect treatment use.
Simply asking patients how their prescribed treatment is going may uncover barriers that would otherwise remain unaddressed.
The Bottom Line: Sometimes It's Not Just the Pelvic Floor
Pelvic health rehabilitation and local hormone therapy should not be viewed as competing approaches. They address different, often overlapping contributors to pelvic symptoms.
Muscle function matters. Nervous system regulation matters. Movement, loading, and behavioral strategies matter. And tissue health matters.
When a patient continues to experience pain, irritation, urinary symptoms, or difficulty tolerating penetration despite appropriate rehabilitation, we need to remain curious about what else may be contributing. Sometimes that means modifying our treatment approach. Sometimes it means recognizing the need for medical management. And sometimes the most valuable intervention we provide is identifying a barrier that requires another member of the healthcare team.
At Professional Pelvic Health Consultants, we believe effective pelvic health rehabilitation requires looking beyond isolated structures and treating the interconnected systems influencing function.
Because the pelvic floor doesn't function independently of the tissues surrounding it. And excellent clinical reasoning means knowing when rehabilitation can address the problem—and when collaboration can help us do more.
References
Kaufman MR, et al. The AUA/SUFU/AUGS Guideline on Genitourinary Syndrome of Menopause. J Urol. 2025. doi:10.1097/JU.0000000000004589
The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020. doi:10.1097/GME.0000000000001609
Rahn DD, et al. Vaginal estrogen for genitourinary syndrome of menopause: a systematic review. Obstet Gynecol. 2014;124(6):1147-1156. doi:10.1097/AOG.0000000000000526
Porcari I, et al. Vulvovaginal estrogen therapy for urinary symptoms in postmenopausal women: a review and meta-analysis. Climacteric. 2025. doi:10.1080/13697137.2025.2517138
Labrie F, et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause. 2016. doi:10.1097/GME.0000000000000571
Labrie F, et al. Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. J Sex Med. 2015. doi:10.1111/jsm.13045
Crandall CJ, et al. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study. Menopause. 2018. doi:10.1097/GME.0000000000000956
Beste, et al. Vaginal estrogen use in breast cancer survivors: a systematic review and meta-analysis of recurrence and mortality risks. Am J Obstet Gynecol. 2024. doi:10.1016/j.ajog.2024.10.054
Cold S, et al. Systemic or Vaginal Hormone Therapy After Early Breast Cancer: A Danish Observational Cohort Study. J Natl Cancer Inst. 2022;114(10):1347-1354. doi:10.1093/jnci/djac112
Sriprasert I, et al. Elimination of the Black Box Warning on Menopausal Hormone Therapy. Obstet Gynecol.2026;147(5):642-646. doi:10.1097/AOG.0000000000006226
The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022. doi:10.1097/GME.0000000000002028
Cardozo L, et al. Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol. 1998. doi:10.1016/s0029-7844(98)00175-6
Santen RJ, et al. Systemic estradiol levels with low-dose vaginal estrogens. Menopause. 2020. doi:10.1097/GME.0000000000001463
Agrawal, et al. A randomized, pilot trial comparing vaginal hyaluronic acid to vaginal estrogen for the treatment of genitourinary syndrome of menopause. Menopause. 2024. doi:10.1097/GME.0000000000002390
Comments